Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6433381

CN(Cc1ccc2c(Cl)cnc(NC(=N)N)c2c1)[C@H](C(=O)O)c1ccccc1.O=C(O)C(F)(F)F

nearest known ligand 0.36

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PLAU P00749 7/20 0.36
NR4A2 P43354 1/20 0.33
S1PR2 O95136 1/20 0.33
S1PR3 Q99500 1/20 0.33
TRPM8 Q7Z2W7 2/20 0.33
PLG P00747 3/20 0.32
PLAT P00750 2/20 0.32
ALDH1A1 P00352 2/20 0.32
CCR2 P41597 1/20 0.31
MDM2 Q00987 1/20 0.31
HDAC3 O15379 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC2 Q92769 1/20 0.31
NCOR2 Q9Y618 1/20 0.31
ITGB1 P05556 1/20 0.31
ITGA4 P13612 1/20 0.31
GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6437525 0.86 PLAU (0.34) PLAUS1PR2S1PR3PLGPLAT
Hydrochloric Acid SCHEMBL6960293 0.85 PLAU (0.33) PLAUS1PR2S1PR3PLGPLAT
SCHEMBL7367873 0.83 PLAU (0.33) PLAUS1PR2S1PR3
Trifluoroacetic Acid SCHEMBL6433433 0.81 PLAU (0.43) PLAUTRPM8PLG
Trifluoroacetic Acid SCHEMBL6432682 0.74 CA2 (0.49) ITGB1ITGA4
Trifluoroacetic Acid SCHEMBL6432685 0.74 CA2 (0.49) ITGB1ITGA4
Trifluoroacetic Acid SCHEMBL6434862 0.73 CTSA (0.42)
Trifluoroacetic Acid SCHEMBL6432939 0.73 F2 (0.47) PLAUPLGPLATALDH1A1
Trifluoroacetic Acid SCHEMBL6437718 0.73 CA2 (0.45) PLAUPLGPLAT
Trifluoroacetic Acid SCHEMBL6437715 0.73 CA2 (0.45) PLAUPLGPLAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed
EP-1077945-A1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2001-02-28 EP disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed
WO-2000005214-A2 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 PLAU 119/4885NR4A2 2698/4885S1PR2 3034/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 PLAU 119/4885NR4A2 2698/4885S1PR2 3034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.